Table 1 Clinical and pathological characteristics of patients with and without Her-2/neu overexpression, c-Kit expression and EGFR expression
Characteristics | All patients ( n =54) | EGFR− ( n =18) | EGFR+ ( n =36) | HER2/neu− ( n =52) | HER2/neu+ ( n =2) | c-KIT− ( n =48) | c-KIT+ ( n =6) |
---|---|---|---|---|---|---|---|
Age (years) | |||||||
Median | 58 | 58 | 55.5 | 58 | 52 | 55.5 | 66.5 |
Range | 33–73 | 33–68 | 41–73 | 33–73 | 45–59 | 33–73 | 48–71 |
Sex | |||||||
Male | 31 (57%) | 10 (55%) | 21 (58%) | 29 (56%) | 2 (100%) | 29 (60%) | 2 (33%) |
Female | 23 (43%) | 8 (45%) | 15 (42%) | 23 (44%) | 0 | 19 (40%) | 4 (67%) |
Pathology | |||||||
Adenocarcinoma | 29 (53%) | 10 (55%) | 19 (53%) | 27 (52%) | 2 (100%) | 27 (56%) | 2 (33%) |
Poorlydifferentiated | 18 (33%) | 7 (38%) | 11 (30%) | 18 (35%) | 0 | 16 (33%) | 2 (33%) |
Undifferentiated | 7 (13%) | 1 (5%) | 6 (17%) | 7 (13%) | 0 | 5 (11%) | 2 (33%) |
Treatment | |||||||
1 | 28 (51%) | 7 (38%) | 21 (58%) | 27 (52%) | 1 (50%) | 27 (56%) | 1 (17%) |
2 | 26 (49%) | 11 (62%) | 15 (42%) | 25 (48%) | 1 (50%) | 21 (44%) | 5 (83%) |
Serum LDH | |||||||
Normal | 26 (48%) | 9 (50%) | 17 (47%) | 26 (50%) | 0 | 23 (48%) | 3 (50%) |
Elevated | 22 (40%) | 8 (45%) | 14 (39%) | 21 (40%) | 1 | 19 (40%) | 3 (50%) |
Not available | 6 (12%) | 1 (5%) | 5 (14%) | 5 | 1 | 6 | 0 |
ECOG PS | |||||||
0 | 43 (79.5%) | 14 (78%) | 29 (80%) | 41 (79%) | 2 | 38 (79%) | 5 (83%) |
1 | 10 (18.5%) | 4 (22%) | 6 (17%) | 10 (19%) | 0 | 9 (19%) | 1 (17%) |
Not available | 1 | 1 | 1 | 0 | 1 | 0 | |
Tumour site | |||||||
Lymph nodes | 32 (60%) | 10 (55%) | 25 (70%) | 35 (67%) | 2 (100%) | 36 (75%) | 4 (66%) |
Liver | 27 (50%) | 11 (60%) | 16 (44%) | 27 (52%) | 0 | 25 (52%) | 2 (33%) |
Lung | 28 (52%) | 11 (60%) | 17 (47%° | 26 (50%) | 2 (100%) | 26 (54%) | 2 (33%) |
Bone | 19 (35%) | 9 (50%) | 10 (28%) | 18 (35%) | 1 (50%) | 18 (37%) | 0 |
Peritoneum | 3 (5%) | 3 (16%) | 9 (25%) | 3 (6%) | 0 | 3 (6%) | 0 |
Adrenal gland | 6 (11%) | 1 (5%) | 5 (14%) | 12 (23%) | 0 | 6 (12%) | 0 |
Pleura | 4 (7%) | 1 (5%) | 3 (8%) | 4 (8%) | 0 | 4 (8%) | 0 |
Brain | 2 (4%) | 0 | 2 (5%) | 2 (4%) | 0 | 1 (2%) | 1 (17%) |
Cutaneous | 1 (2%) | 0 | 1 (2.5%) | 1 (2%) | 0 | 1 (2%) | 0 |
Others | 10 (18%) | 4 (22%) | 6 (17%) | 10 (19%) | 0 | 10 (21%) | 0 |